Nurix, Inc. announced the promotion of Pierre Beaurang, Ph.D., to chief business officer. In addition, the company has appointed former interim chief financial officer Hans van Houte to the position of vice president of finance. Dr. Beaurang joined Nurix as vice president of business and corporate development in August 2014 and is responsible for developing Nurix’s partnering strategy. Prior to joining Nurix, Dr. Beaurang was part of the founding team of Five Prime Therapeutics. Mr. van Houte has served as Nurix’s interim CFO since April 2014 and has served in a similar capacity for multiple new biotechnology companies formed with investments totaling over $100 million from Third Rock Ventures and The Column Group. Prior to Nurix, he held senior financial roles including vice president, finance and administration at Trubion Pharmaceuticals and controller, treasurer and principal accounting officer at Vertex Pharmaceuticals.